PureTech Health plc News

PTCHFDelisted Stock  USD 3.13  0.00  0.00%   
Roughly 56% of PureTech Health's investor base is looking to short. The analysis of overall sentiment of trading PureTech Health plc pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with PureTech Health's historical and current headlines, can help investors time the market. In addition, many technical investors use PureTech Health plc stock news signals to limit their universe of possible portfolio assets.
PureTech Health pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of PureTech daily returns and investor perception about the current price of PureTech Health plc as well as its diversification or hedging effects on your existing portfolios.
  
over two weeks ago at gurufocus.com         
Deep Track Capital, LP Reduces Stake in Dyne Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Apellis Pharmaceuticals Given New 47.00 Price Target at Bank of America
news
over three weeks ago at globenewswire.com         
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 F...
Yahoo News
over a week ago at news.google.com         
104,535 Shares in Terns Pharmaceuticals, Inc. Purchased by Quest Partners LLC - MarketBeat
Google News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Iain Ross Buys 1,100,000 Shares of Tern Plc Stock
news
over a month ago at finance.yahoo.com         
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635
Yahoo News
over a month ago at thelincolnianonline.com         
Dawn Protocol Hits Market Capitalization of 167,632.91
news
over three weeks ago at gurufocus.com         
Disposition of 11245 shares by Blackman Samuel C. of Day One at 16.0326 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at prnewswire.com         
SUNDECK 3200 HERALDS IN A NEW DAWN FOR HURRICANE BOATS
prnewswire News
over three weeks ago at investing.com         
Earnings call Blueprint Medicines sees revenue soar with AYVAKIT sales
Investing News at Macroaxis
over two weeks ago at benzinga.com         
Blood Cancer-Focused Blueprint Medicines Could Be Attractive Target For Partnerships Analyst
benzinga news
over three weeks ago at investors.com         
Stocks Showing Improved Relative Strength Blueprint Medicines
Investors Business Daily at Macroaxis
over three months ago at channelnewsasia.com         
Oil tanker in collision near Pedra Branca did not flee, but had drifted away Malaysian authorities
news
over three months ago at news.google.com         
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie - Seeking A...
Google News at Macroaxis
over three months ago at finance.yahoo.com         
10 clinical trials to watch in the second half of 2024
Yahoo News
over three months ago at talkmarkets.com         
AbbVie Stock Price Forecast 200 On The Cards?
news
over a year ago at seekingalpha.com         
Iveric Bio shares fall amid concern about Astellas deal
seekingalpha News
over a year ago at thelincolnianonline.com         
IVERIC bio, Inc. Receives 19.00 Average Price Target from Analysts
news
over a year ago at benzinga.com         
Eye Care Sector Sees Several Large Acquisitions Could This Ticker Be On Route For The Next Big Acqui...
benzinga news
over a year ago at news.google.com         
Form PREM14A IVERIC bio, Inc. For May 23 - StreetInsider.com
Google News at Macroaxis
over a week ago at seekingalpha.com         
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise
seekingalpha News
over a month ago at businesswire.com         
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonst...
businesswire News
over three weeks ago at simplywall.st         
Disposition of 63690 shares by Justin Klee of Amylyx Pharmaceuticals at 1.57 subject to Rule 16b-3
Simply Wall St News at Macroaxis
over two weeks ago at simplywall.st         
Is Immix Biopharma In A Good Position To Deliver On Growth Plans?
Simply Wall St News at Macroaxis
over a month ago at finance.yahoo.com         
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial N...
Yahoo News
over two months ago at news.google.com         
Immix Biopharma stock hits 52-week low at 1.74 amid market challenges - Investing.com
Google News at Macroaxis
few days ago at globenewswire.com         
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology Annua...
Macroaxis News: globenewswire.com
over three weeks ago at finance.yahoo.com         
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibitio...
Yahoo News
over a month ago at globenewswire.com         
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC ...
Macroaxis News: globenewswire.com
over two weeks ago at gurufocus.com         
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com
Google News at Macroaxis
over a week ago at investing.com         
Hepion Pharmaceuticals faces Nasdaq delisting risk
Investing News at Macroaxis
over three months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
AVRO Stock Earnings Avrobio Beats EPS for Q1 2024
sbwire news
over three months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over six months ago at globenewswire.com         
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponso...
Macroaxis News: globenewswire.com
over six months ago at investorplace.com         
EFTR Stock Earnings eFFECTOR Therapeutics Meets EPS for Q1 2024
sbwire news
over six months ago at news.google.com         
Head to Head Survey eFFECTOR Therapeutics versus COMPASS Pathways - Defense World
Google News at Macroaxis
over three months ago at benzinga.com         
Dow Jumps 300 Points Alimera Sciences Shares Spike Higher
benzinga news
Far too much social signal, news, headlines, and media speculation about PureTech Health that are available to investors today. That information is available publicly through PureTech media outlets and privately through word of mouth or via PureTech internal channels. However, regardless of the origin, that massive amount of PureTech data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PureTech Health news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PureTech Health relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PureTech Health's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PureTech Health alpha.

PureTech Health Performance against Dow Jones

 Price Growth (%)  
       Timeline  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in PureTech Pink Sheet

If you are still planning to invest in PureTech Health plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PureTech Health's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Transaction History
View history of all your transactions and understand their impact on performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Fundamental Analysis
View fundamental data based on most recent published financial statements
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments